

DR ANNA HEDMAN (Orcid ID : 0000-0001-9888-1659)

PROFESSOR CATARINA ALMQVIST (Orcid ID : 0000-0002-1045-1898)

DR BJÖRN NORDLUND (Orcid ID : 0000-0001-9888-1659)

Article type : Original

Genetic effects of allergen-specific IgE-levels on exhaled nitric oxide in schoolchildren with asthma: the STOPPA twin study

Running title: A twin study of asthma phenotypes

Anna M. Hedman¹, Ralf Kuja-Halkola¹, Anne K. Örtqvist^{2,3}, Marianne van Hage⁴, Catarina Almqvist^{1,5}, Björn Nordlund^{5,6}

Manuscript word count: 3,824

Table count: 3

Figure count: 2

Affiliations:

¹ Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

² Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/pai.13438](https://doi.org/10.1111/pai.13438)

This article is protected by copyright. All rights reserved

³ Department of Obstetrics and Gynecology, Visby lasarett, Gotland, Sweden

⁴ Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.

⁵ Pediatric Allergy and Pulmonology Unit, Astrid Lindgren Children's Hospital; Karolinska University Hospital, Stockholm, Sweden.

⁶ Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.

Corresponding author:

Anna M. Hedman

Department of Medical Epidemiology and Biostatistics

PO Box 281, Karolinska Institutet, SE-171 77 Stockholm, Sweden

Phone: +46 (0)8-52485285

E-mail: anna.hedman@ki.se

This study contains material in the electronic repository.

The authors report no conflict of interest related to the manuscript content.

Abstract

Background: Exhaled nitric oxide and blood eosinophils are clinical asthma T-helper type 2 markers in use. Immunoglobulin E (IgE) is often involved in the inflammation associated with atopic asthma. The effect of both blood eosinophils and allergen-specific IgE on exhaled nitric oxide levels is not completely understood. Twin-design studies can improve understanding of the underlying contribution of genetically and/or environmentally driven inflammation markers in asthma. Our aim was to disentangle the covariance between asthma and exhaled nitric oxide into genetic and environmental contributions that can account for inflammation markers in a pediatric population.

Methods: This population-based, cross-sectional twin study enrolled 612 monozygotic (MZ) and same-sex dizygotic (DZ) schoolchildren. Multivariate structural equation modelling was utilized to separate the covariance between asthma and exhaled nitric oxide into genetic and/or environmental effects, taking allergen-specific IgE level and blood eosinophil count into account while controlling for confounding factors.

Results: The cross-twin/cross-trait correlations had a higher magnitude in the MZ twins than in the DZ twins indicating that genes affect the association. The likelihood ratio test for model fitting resulted in the AE model (i.e., additive genetic effects, A, and non-shared environmental effects, E) as the most parsimonious. A majority, 73%, of the phenotypic correlation between asthma and exhaled nitric oxide, $r=0.19$ (0.05–0.33), was attributable to genetic effects which mainly was due to the allergen-specific IgE level.

Conclusions: This study indicate that the association between asthma and exhaled nitric oxide in children is to a large extent explained by genetics via allergen-specific IgE-level and not blood eosinophils. This might partly explain the clinical heterogeneity in this group. A next step could be to include allergen-specific IgE level in multivariate omic-studies.

Word count abstract: 275

Keywords: Eosinophils, Immunoglobulin E, Inflammation, twins

Key Message

Allergen-specific IgE level impacts the association between asthma and FE_{NO} by a genetic component. This may give us a hint of including IgE-diagnostics when treating and managing asthma according to FE_{NO} -levels in the future.

Introduction

Asthma is the most common chronic disease in children¹ and it is defined as an obstructive and often underlying airway inflammatory disease.² T-helper type 2 (T2) responses are thought to be central mediators of inflammation in asthma³ and a widely used clinical marker to measure possible T2 inflammation is exhaled nitric oxide (FE_{NO}).^{3,4}

FE_{NO} is easy to measure in exhaled breath, and its level corresponds directly with asthma and inflammation in the bronchial epithelium.⁵ FE_{NO} can therefore aid asthma diagnosis, and, if correctly applied and interpreted, identify patients at risk of exacerbation.⁶ In clinical practice, generalized cut-off values of FE_{NO} have so far been difficult to translate to individual patients due to unknown contribution of factors that influence the FE_{NO} value, such as allergen-specific immunoglobulin E level (IgE), blood eosinophil counts,⁷ tobacco smoke exposure,⁸ upper airway infection, age, and height.⁹

The interest of measuring the number of blood eosinophils has increased in recent years since the introduction of anti-interleukin-5 therapy for severe eosinophil asthma.¹⁰ High blood eosinophils appear to be related to poor asthma control, hospitalisation¹¹ and reduced lung function development in adults.¹² Hence, both FE_{NO} and blood eosinophil count reflects ongoing T2 inflammation. However, the inflammatory contribution of blood eosinophil counts on the association between asthma and FE_{NO} is debated and not completely understood.¹¹ FE_{NO} levels are activated by interleukin-4/-13 and blood eosinophil count by interleukin-5.¹³ However, these markers may play a very different role in adults and children due to differences in underlying pathophysiology.¹⁴ Nonallergic eosinophilic asthma, not mediated by specific IgE, develops later in life and is rarely present in childhood,¹⁵ indicating different mechanisms involved in regulating FE_{NO} and eosinophils in children and adults. IgE is an important clinical biomarker, which is often involved in atopic asthma, the most common form of asthma in children.¹⁶ The airway inflammation involved in atopic asthma is recognized with both increased total IgE concentration and an elevated FE_{NO} fraction, as well as activation of eosinophilic granulocytes.^{16,17} In sensitized children, blood

eosinophil count has been shown to be associated with increased level of FE_{NO}.¹⁸ Still, the relative contribution of allergen-specific IgE level and blood eosinophil count on FE_{NO} in children with asthma is not established.

Twin studies provide a unique method for determining the contribution of genetic and environmental sources of variation in a disease or a phenotype.¹⁹ The multivariate twin design can aid in the estimation of the same genetic and/or environmental factors that influence different diseases and intermediate phenotypes.²⁰ This can broaden our understanding of asthma biomarkers and inform gene-mapping efforts.²¹ We have previously shown that the association between asthma and FE_{NO} was mainly explained by genetics and allergic sensitization.²² Therefore, our goal here was to further disentangle the association between asthma and FE_{NO}, by estimating the relative contribution of genetic and/or environmental effects from both allergen-specific IgE level and blood eosinophils. These potential shared genetic origins and environmental contributions will be studied in a multivariate twin study, thereby avoiding inflated type 1 error by multiple testing.

Methods

Study design and study sample

The Swedish Twin Study on Prediction and Prevention of Asthma (STOPPA) is a population-based, cross-sectional twin study on childhood asthma in discordant, concordant, and healthy concordant twins.²³ The study participants were recruited from the Child and Adolescent Twin Study in Sweden (CATSS),²⁴ a study initiated in 2004 that included all twins born from July 1992 and onwards, identified through the Swedish Twin Registry.²⁵ Validated questions on asthma ever (yes/no) '*Does he/she have, or has he/she had asthma?*'^{24,26} and wheezing (current or after three years of age) according to the International Study of Asthma and Allergies in Childhood (ISAAC) were used to identify 9- to 14-year-old twins discordant and concordant for asthma or wheeze and healthy control

twins.²⁶ Monozygotic (MZ) and same-sex dizygotic (DZ) twin pairs who were raised together were recruited to STOPPA from all parts of Sweden and distributed throughout the whole year.

Participants were invited to a clinical examination including questionnaires and objective measures at eight different study sites.²³ The study population (n = 752) was classified as asthma concordant (31%), asthma discordant (38%), and healthy concordant (31%), according to the recruitment algorithm of asthma status, as described in detail elsewhere.²³ One twin pair had unknown zygosity and 53 did not consent to blood sampling. The final analytic sample consisted of 612 individuals (81.4% of the study population with full information on exposure and all covariates). The study was approved by the Regional Ethical review board in Stockholm, Sweden. Informed consent was obtained from all the participants and their parents.

Variables

Asthma. All twins and their parents completed questionnaires. The parental questionnaire, which has previously been validated against health care registers with good agreement,²⁷ included questions on the parent's lifestyle, background, and medical history, followed by a section on each twin's general health status, lifestyle, and medical history including current asthma defined as reporting positively to the question '*Does your child have asthma?*'.²³

FE_{NO}. Exhaled nitric oxide was measured during an exhalation of at least 6 seconds at a flow of 50 ml/s (FE_{NO}), measured with a hand-held electrochemical analyzer (NIOX Mino, Aerocrine, Solna, Sweden) according to the guidelines.²⁸ The average integer value of FE_{NO} (parts per billion) was recorded based on two consecutive measurements if they differed by less than 5% or based on three measurements if they differed by >5%.

Sensitization to airborne allergens. More than 90% of the participants underwent blood sampling, and serum was analysed for IgE antibodies to Phadiatop®, Thermo Fisher Scientific, Uppsala, Sweden, a screening test for sensitization to a mix of common inhalant allergens (birch, timothy,

mugwort, cat, dog, horse, house dust mites [*Dermatophagoides pteronyssinus* and *farina*], and mold [*Cladosporium herbarum*]). Sensitization was regarded as a level of ≥ 0.35 kU_A/L corresponding to a fluorescence intensity of 168 response units and this defined the categorical (1/0) *IgE positive* variable. The numeric IgE level to Phadiatop®, here termed the *allergen-specific IgE level*, was used as a continuous IgE variable and has been described previously.²⁹ IgE values below the level of quantification of 0.1 kU_A/L were assigned a value 0.09 kU_A/L, and values above 100 kU_A/L were set at 100 kU_A/L, as described elsewhere.³⁰ All samples were analysed at the Department of Clinical Immunology and Transfusion Medicine at the Karolinska University Hospital Solna, Sweden.

Eosinophils. Samples of venous blood were collected in 4 ml EDTA tubes and transported to the local chemistry laboratory for analysis of white blood cell count including blood eosinophils (1×10^9 counts/L) according to standard operating procedure at each specific site.

Inhaled corticosteroids. Parents confirmed inhaled corticosteroid (ICS) treatment by answering yes to the questions '*Does he/she have, or has he/she had asthma?*'²⁴ and '*Has your child used ICS treatment regularly during the last 12 months?*'

Zygosity. Data on zygosity were retrieved from the CATSS study. A majority of the twins had their zygosity determined by DNA analysis (84.3%), with the remaining assessed via an algorithm of five questions on twin similarity, a validated technique to determine zygosity with at least 95% accuracy.²⁴

Age. Information on age was collected from the questionnaire and is included as a covariate in the analyses. Age when samples were taken was calculated as date of measurement minus date of birth.

Socioeconomic status (SES). As a proxy for SES, we used the parental (maternal or paternal) highest education retrieved from the questionnaire.

Any parental asthma. To assess the parental history of asthma, we collected the following item from the questionnaires: '*Does the mother/father have asthma?*' and created a new variable 'any parental asthma,' based on whether either the mother or father or both had asthma.

Parental current smoking. Smoking was assessed from the questionnaire with the following question: ‘Does the mum/dad smoke?’

Statistical Analyses

We analysed asthma, FE_{NO}, allergen-specific IgE level, and eosinophils, in a four-variate twin model. In this model, the covariance between variables within individuals, as well as the covariance between twins in pairs, are explicitly modelled in structural equation models. Asthma was analyzed as a binary variable and adjusted for age and sex. The data for FE_{NO}, allergen-specific IgE level, and eosinophils were all log-transformed to obtain a distribution closer to normal, and adjustments were done for ICS, age and sex. Due to the sampling scheme, the population may have a skewed distribution (compared to the source population) of investigated variables; thus, we re-weighted all analyses according to sampling probability.

Assumptions testing

First, a saturated model was fitted, which included separate estimates for means, prevalence rates, variances, and covariances between ‘twin 1’ and ‘twin 2,’ according to random assignment for order in pairs and separately between MZ and DZ twin pairs. We then proceeded to fit a model where we assumed symmetry within each zygosity, i.e., the twin order was not associated with means/prevalences and variances or with within-individual covariance between the traits, named “Symmetric”. Finally, a model where means and variances were additionally assumed to be the same across zygosity was fitted corresponding to the basic assumptions needed for a quantitative genetic model, named “Assumption.”

Observed correlations

We presented correlations from the “Symmetric” model described above. The phenotypic correlations, r_{ph} , were based on the within-twin/cross-trait correlations. Intra-class correlations (ICC) are the correlations between the same variable measured in one twin and in his/her co-twin (i.e.,

cross-twin/within-trait). If the absolute value of ICC is larger in MZ twins than in DZ twins, this indicates that genes are involved in the association. The cross-twin/cross-trait (CTCT) correlations represents the correlations between one variable in one twin and another in the co-twin. If the absolute value of the CTCT is larger in MZ twins than in DZ twins, this implies that genes influencing both traits (at least partly) overlap. Pearson correlations were calculated for the associations between continuous traits, while tetrachoric for binary (asthma) and biserial correlations were calculated for both binary and continuous traits.

Quantitative genetic model

Based on the differences in genetic similarity for twins with different zygositys, MZ twins have a correlation of 1 for additive genetic effects (A), representing the combined effect of alleles at a locus and across loci that add up, whereas DZ twins have a correlation of 0.5³¹ Dominance genetic effects (D or d^2) also contribute to twin pair similarity and the index interaction of gene alleles at the same locus (dominance), and are assumed correlated 1 between MZ-twins and 0.25 between DZ-twins. Furthermore, both types of twins are assumed to have an equal correlation of 1 for environmental effects that both twins share (C or c^2), such as perinatal and home environment, whereas unique environmental effects that twins in pairs do not share (E or e^2), such as accidents, are modelled with a correlation of 0 between twins. Thus, a higher correlation in MZ twins than in DZ twins would represent the effect of the higher proportion of genes shared among MZ twins.³²

The multivariate genetic model estimates the genetic and environmental contributions to the phenotypic correlation between asthma and FE_{NO} and the degree that can be accounted for by sensitization to aeroallergens and blood eosinophils. The phenotypic correlations were decomposed into combinations of A, D, C, and E, depending on which model was fitted. We fitted a series of structural equation models estimating the maximum-likelihood genetic and environmental variance components of variables, and the covariance between these. We performed likelihood ratio tests to find the best-fitting model.

We were interested in the correlation between asthma and FE_{NO} and what potentially could affect this correlation in terms of genetic and environmental influences from other factors. Therefore, we proceeded to fit a four-variate “Cholesky model” to disentangle the sources of variance and covariance into genes and environment. In a Cholesky model, the order the variables appear is important; the “left” variables influence the variables to the “right,” but not vice versa³³ (see Figure 1) to allow estimation of the influence (i.e., genetic and/or environmental) of allergen-specific IgE level and eosinophils on the association between asthma and FE_{NO} . Since we were interested if allergen-specific IgE level and eosinophils could influence asthma and FE_{NO} we decided to model the variables in this order.

We fitted an ACE model, i.e., a model with A, C, and E sources of variance and covariance. We also fitted an ADE model, AE model, and CE model. We tested whether the nested models had poorer fits to the data using likelihood ratio tests. We also used the Akaike's Information Criterion (AIC) to assess the model fit. The AIC favors model parsimony and allows for comparisons across non-nested models. In addition, we compared other models with the ACE model (base) to assess model fit.

Figure 1 shows the Cholesky model (here, the AE model is taken as an example) with the observed variables (eosinophils, allergen-specific IgE level, asthma, and FE_{NO}) in relation to the unobserved latent factors which constitute of additive genetic effects and unique/unshared environmental effects (A_{1-4} and E_{1-4} respectively), here represented by circles, which are connected by the paths a_{11-44} and e_{11-44} . Thus, the variance in, and covariance between, asthma and FE_{NO} may be explained by the variance in eosinophils and allergen-specific IgE level, but not vice versa. Analyses were performed using the statistical software R,³⁴ version 3.6.1, and the package OpenMx³³, version 2.15.5.

Additional details on calculated contributions to the correlations between asthma and FE_{NO} are provided in the Online Supplemental material.

Sensitivity analyses

In addition, to instigate the potential effect of the season, when the samples were taken, in sensitivity analyses we additionally adjusted for season at sampling-time.

Results

Table 1 gives an overview of the study population which had a mean age of about 12.5 years in both groups and with 58% males in the current asthma group. The percentage of any parental asthma was higher in the asthma group (46%) than in the group reported no current asthma (16%). The geometric means of FE_{NO} and the allergen-specific IgE level were higher (18 and 2.3 respectively) in the asthma group than in the no current asthma group (12.9 and 0.3, respectively). The mean blood eosinophil count was higher in the asthma group (0.4 vs. 0.3), but the reported ICS was lower in the no current asthma group, at 0.2%, than in the asthma group, at 34.6%.

Here, we will only present results from models using the continuous variable allergen-specific IgE level to maximize statistical power. The Online Supplemental material shows results for the dichotomous variable IgE positive.

Observed correlations

The “Symmetric” model provides estimates of correlations, as estimated for MZ and DZ independently, and as all twins together (Table 2).

Table 2 present observed maximum likelihood correlations. Most r_{ph} correlations were statistically significantly different from 0, and about the same magnitude in both the MZ and DZ twins (except for the correlation between eosinophils and asthma which was 0.29 and significant in MZ twins but was -0.05 and non-significant in DZ twins), indicating that all variables are associated within individuals. All ICCs were statistically significantly different from 0 and higher in the MZ twins than in the DZ twins, indicating a heritable component for the univariate measures. All CTCTs had a higher

magnitude in the MZ twins than in the DZ twins indicating that genes affect the association between all variables.

Model fitting

The likelihood ratio test was first compared with the saturated model (ETable 2A Online Data Supplement) and then with the ACE model (ETable 2B, with best likelihood among quantitative genetic models). A statistically non-significant drop in fit ($p=0.884$) was observed when comparing the AE model against the ACE model, making the AE model the most parsimonious/final model (ETable 2B).

Quantitative genetic model

Figure 2 and Table 3 presents the correlation between asthma and FE_{NO} separated into genetic and environmental sources. These were factors uniquely related to allergen-specific IgE level, factors unique to eosinophils, factors shared by allergen-specific IgE level and eosinophils, and factors shared between asthma and FE_{NO} , as estimated in the (best-fitting) AE model (Online Supplemental method outlines how the separation into unique and shared sources has been achieved).

In the best-fitting AE model, a significant phenotypic correlation, r_{ph} , was noted between asthma and FE_{NO} ($r_{ph} = 0.19$; Table 3). The part of the phenotypic correlation, which can be attributable to additive genetic effects, r_{ph-a} , due to allergen-specific IgE level was statistically significant ($r_{ph-a} = 0.10$) and accounted for half (54%) of the correlation between asthma and FE_{NO} . All other estimates were non-significant.

Other quantitative genetic models (ACE, ADE and CE), the path coefficients from the AE model, as well as the heritability estimates, are shown in Online Data Supplement, ETable 3, ETable 4A-B.

Twin correlations and results from the quantitative genetic models obtained when the categorical variable IgE positive was used instead of allergen-specific IgE level can be found in the Online Supplemental material, ETables 5–6. Overall, the results using the categorical IgE positive were very similar to the results obtained from the continuous allergen-specific IgE level.

Sensitivity analyses

Results from the sensitivity analyses when season at sampling-time was added as a covariate can be found in the Online Supplemental material, ETables7-11B and EFigure2. Overall, the results were very similar and no differences from the original analyses were found.

Discussion

In this population-based twin study, we disentangled the genetic and environmental sources of covariation between asthma and FE_{NO} by analysing the effect of blood eosinophils and allergen-specific IgE-level. More than half (54%) in the total covariance between FE_{NO} and asthma was due to genetically driven effects of the IgE level to airborne allergens. Thus, our results indicate that genetically driven allergen-specific IgE level, but not blood eosinophil counts, is part of the same underlying construct that creates significant correlation between asthma and FE_{NO} in schoolchildren.

This study provides further understanding of genetic influence from the allergen-specific IgE level on FE_{NO} in children with asthma. Complex genetic inheritance in asthma susceptibility has been reported, where more than one hundred genetic variants have been implicated.³⁵ Although just a subset of these genetic variants has been replicated, the genetic contribution to the asthma and FE_{NO} association seems unclear.²² Genetic studies have found a link between FE_{NO} values and a few genetic loci^{36,37} and the genetics of the IL-4/IL-13 pathway have been linked to IgE levels of childhood asthma.^{38,39} Interestingly, Thomsen et al. studied the covariance between FE_{NO} and total IgE and found that 93% of the phenotypic correlation could be explained by genetic factors.⁴⁰ Thus, previous results point to the fact that genetics play an important role in the allergic asthma phenotype. Here, we show that allergen-specific IgE level, but not blood eosinophils, highly impacts the asthma FE_{NO} association by a genetic component. This may give us a hint of including IgE-diagnostics when treating and managing childhood asthma according to FE_{NO} -levels in the future.

Previous twin research on asthma phenotypes has applied bivariate modelling to their data,^{21,40-43} thereby separating the covariance of genetic and environmental determinants from two sources. Results within these bivariate studies point to a large extent of a common genetic background between asthma phenotypes.⁴⁰⁻⁴³ Here, we include a multivariate modelling with four different sources to investigate whether they share common genetic and/or environmental origins. The advantage of using a multivariate over a bivariate model is that the relationships between several variables can be found simultaneously. Allergen-specific IgE level can be considered a cause of allergic asthma as it is involved early in the inflammatory process which also implicates an increase in eosinophils.⁴⁴ Here we found significant genetic influence from allergen-specific IgE level but not from eosinophils, indicating that increased FE_{NO} level is mostly reflected in allergic childhood asthma activated by inflammatory cytokines IL-4 and IL-13, but not IL-5.⁴⁴ However, caution is warranted when generalizing our results to subjects other than children in this age-range, since reports show an age-dependent interaction between sensitization and elevated eosinophil levels in asthma cases.⁴⁵ Allergic eosinophilic asthma in children often coexist with allergic sensitization,⁴⁶ while the late onset phenotype, nonallergic eosinophilic asthma, is not induced by specific allergens.⁴⁶ In addition, the cellular component of inflammation may not be adequately represented by eosinophilic granulocytes since innate lymphoid cells (ILC2) are suggested to be more relevant markers.^{47,48}

The major strength of our study is that we used a population-based twin sample of children. We have also used reliable objective biomarkers and the asthma status was based on definitions from the ISAAC study.⁴⁹ Another strength of our study is that we included both a continuous and dichotomous IgE variable on sensitization to aeroallergens. This continuous measure enabled us to utilize all the information about the allergen-specific IgE level variable by maximizing the statistical power. Levels below 0.35kU_A/L can provide additional prognostic information, since results have shown that children who show low sensitization (i.e., 0.10–0.34 kU_A/L) to food allergens in infancy seem to have an increased probability of sensitization to aeroallergens in later life.⁵⁰ Furthermore, we adjusted for age, sex and ICS use and we re-weighted the analyses by sampling probability. We

assumed that the tobacco use would be minor since of the age of the children, thus we did not include it as a covariate. Limitations include the inherently low power of the classical twin method to detect effects of a shared environment. This may partly explain the absence of shared environmental factors, C, even though we used a population-based twin sample. Factors that are shared within twin pairs, such as socio-economic status, that we not did control for, would end up as C in the models. One might further question the generalizability of the results from twin studies to the general population. Twins differ from singletons in that they are, on average, born smaller; however, we have previously shown that, after taking gestational age into account, twins are not at a higher risk of asthma.⁵¹ Studies in epigenetic markers of DNA-methylation and gene expression has demonstrated that twins, already at birth, exhibit a large range of epigenetic discordance.^{52,53} Thus, twin similarities can also be produced by epigenetic components in addition to the genome.

Asthma is a complex disease characterized by a set of genetically heterogeneous phenotypes. As new phenotypes for asthma are discovered, twin studies provide a first effort in determining the contribution of genetic and environmental factors to these traits.⁵⁴ We are not aware of any other studies that have estimated the proportion of covariance by genetic and environmental effects of inflammatory markers (i.e., allergen-specific IgE level and eosinophils) on the asthma vs. FE_{NO} association. The source of the high variability in individual FE_{NO} levels in asthmatics is largely unknown, but the present study results may give a partial explanation for this heterogeneity. Thus, the biological background of inflammation should be considered for future personalized medicine.

Conclusions

This study provides further understanding of genetic influence from allergen-specific IgE-level, but not blood eosinophils, on the FE_{NO} asthma association. The results presented here shed new light on the clinical heterogeneity of FE_{NO} values in asthmatic children. As a next step this could encourage omic-studies taking the allergen-specific IgE level into account when investigating inflammation-markers in children with asthma.

Acknowledgments: Financial support was provided from the Swedish Research Council grant no 2018-02640 and through the Swedish initiative for Research on Microdata in the Social and Medical Sciences (SIMSAM) framework grant no 340-2013-5867, grants provided by the Stockholm County Council (ALF-projects and Funding for healthcare personnel), the Strategic Research Program in Epidemiology at Karolinska Institutet, the Swedish Heart-Lung Foundation, the Swedish Asthma and Allergy Association's Research Foundation, the Cancer and Allergy Foundation, Fredrik and Ingrid Thuring's Foundation, King Gustaf V 80th Birthday Foundation and Stiftelsen Frimurare Barnhuset Stockholm. Allergen extracts for IgE analyses were provided by Thermo Fisher, Uppsala, Sweden. Competing financial interests: M van Hage has received lecture fees from Thermo Fisher Scientific.

References

1. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. *Lancet*. 1998;351(9111):1225-1232.
2. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2019. <https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wmspdf> 2019;Access 2019.10.30.
3. Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. *Am J Respir Crit Care Med*. 2009;180(5):388-395.
4. Palmer L, Cookson W. Atopy and asthma. In: Bishop T, Sham P, eds. *Analysis of multifactorial disease*. Oxford: BIOS; 2000.
5. Alving K, Weitzberg E, Lundberg JM. Increased amount of nitric oxide in exhaled air of asthmatics. *The European respiratory journal*. 1993;6(9):1368-1370.
6. Ludviksdottir D, Diamant Z, Alving K, Bjermer L, Malinovschi A. Clinical aspects of using exhaled NO in asthma diagnosis and management. *Clin Respir J*. 2012;6(4):193-207.
7. Shrestha SK, Drews A, Sharma L, Pant S, Shrestha S, Neopane A. Relationship between total serum immunoglobulin E levels, fractional exhaled breath nitric oxide levels and absolute blood eosinophil

- counts in atopic and non-atopic asthma: a controlled comparative study. *Journal of breath research*. 2018;12(2):026009.
8. Persson MG, Zetterstrom O, Agrenius V, Ihre E, Gustafsson LE. Single-breath nitric oxide measurements in asthmatic patients and smokers. *Lancet*. 1994;343(8890):146-147.
 9. Olin AC, Rosengren A, Thelle DS, Lissner L, Bake B, Toren K. Height, age, and atopy are associated with fraction of exhaled nitric oxide in a large adult general population sample. *Chest*. 2006;130(5):1319-1325.
 10. Zarogiannis S, Gourgoulanis KI, Kostikas K. Anti-interleukin-5 therapy and severe asthma. *N Engl J Med*. 2009;360(24):2576; author reply 2577.
 11. Kerkhof M, Tran TN, van den Berge M, et al. Association between blood eosinophil count and risk of readmission for patients with asthma: Historical cohort study. *PLoS One*. 2018;13(7):e0201143.
 12. Hancox RJ, Pavord ID, Sears MR. Associations between blood eosinophils and decline in lung function among adults with and without asthma. *The European respiratory journal*. 2018;51(4).
 13. Mogensen I, James A, Malinovschi A. Systemic and breath biomarkers for asthma: an update. *Curr Opin Allergy Clin Immunol*. 2020;20(1):71-79.
 14. Fuchs O, Bahmer T, Rabe KF, von Mutius E. Asthma transition from childhood into adulthood. *Lancet Respir Med*. 2017;5(3):224-234.
 15. Godar M, Blanchetot C, de Haard H, Lambrecht BN, Brusselle G. Personalized medicine with biologics for severe type 2 asthma: current status and future prospects. *MAbs*. 2018;10(1):34-45.
 16. Martinez FD, Vercelli D. Asthma. *Lancet*. 2013;382(9901):1360-1372.
 17. Amaral AFS, Newson RB, Abramson MJ, et al. Changes in IgE sensitization and total IgE levels over 20 years of follow-up. *J Allergy Clin Immunol*. 2016;137(6):1788-1795.e1789.
 18. Barreto M, Villa MP, Monti F, et al. Additive effect of eosinophilia and atopy on exhaled nitric oxide levels in children with or without a history of respiratory symptoms. *Pediatr Allergy Immunol*. 2005;16(1):52-58.
 19. Los H, Koppelman GH, Postma DS. The importance of genetic influences in asthma. *The European respiratory journal*. 1999;14(5):1210-1227.
 20. Posthuma D, Beem AL, de Geus EJ, et al. Theory and practice in quantitative genetics. *Twin Res*. 2003;6(5):361-376.

21. Thomsen SF, Kyvik KO, Backer V. Etiological relationships in atopy: a review of twin studies. *Twin Res Hum Genet.* 2008;11(2):112-120.
22. Nordlund B, Lundholm C, Ullemar V, van Hage M, Ortqvist AK, Almquist C. The STOPPA Twin Study Explains the Exhaled Nitric Oxide and Asthma Link by Genetics and Sensitization. *Twin Res Hum Genet.* 2017;20(4):330-337.
23. Almquist C, Ortqvist AK, Ullemar V, Lundholm C, Lichtenstein P, Magnusson PK. Cohort Profile: Swedish Twin Study on Prediction and Prevention of Asthma (STOPPA). *Twin Res Hum Genet.* 2015;18(3):273-280.
24. Anckarsater H, Lundstrom S, Kollberg L, et al. The Child and Adolescent Twin Study in Sweden (CATSS). *Twin Res Hum Genet.* 2011;14(6):495-508.
25. Magnusson PK, Almquist C, Rahman I, et al. The Swedish Twin Registry: establishment of a biobank and other recent developments. *Twin Res Hum Genet.* 2013;16(1):317-329.
26. Asher MI, Keil U, Anderson HR, et al. International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods. *Eur Respir J.* 1995;8(3):483-491.
27. Hedman AM, Gong T, Lundholm C, et al. Agreement between asthma questionnaire and health care register data. *Pharmacoepidemiol Drug Saf.* 2018;27(10):1139-1146.
28. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. *Am J Respir Crit Care Med.* 2005;171(8):912-930.
29. Nilsson SF, Lilja G, Jarnbert-Pettersson H, Alm J. Relevance of low specific IgE levels to egg, milk and peanut in infancy. *Clin Exp Allergy.* 2018.
30. Lindemalm C, Nordlund B, Ortqvist AK, et al. Associations Between Asthma and Sensitization to Pet or Pollen Allergens in Young Swedish Twins - The STOPPA Study. *Twin Res Hum Genet.* 2017;20(5):380-388.
31. Purcell S. Statistical Methods in Behavioral Genetics. In: Plomin R, DeFries JC, McClearn GE, P M, eds. *Behavioral Genetics.* 4th ed. New York, NY: Worth; 2001.
32. Rijdsdijk FV, Sham PC. Analytic approaches to twin data using structural equation models. *Brief Bioinform.* 2002;3(2):119-133.
33. Boker S, Neale M, Maes H, et al. OpenMx: An Open Source Extended Structural Equation Modeling Framework. *Psychometrika.* 2011;76(2):306-317.

34. R Core Team. *R: A language and environment for statistical computing*. Vienna, Austria: R Foundation for Statistical Computing; 2017.
35. Vercelli D. Discovering susceptibility genes for asthma and allergy. *Nat Rev Immunol*. 2008;8(3):169-182.
36. van der Valk RJ, Duijts L, Timpson NJ, et al. Fraction of exhaled nitric oxide values in childhood are associated with 17q11.2-q12 and 17q12-q21 variants. *J Allergy Clin Immunol*. 2014;134(1):46-55.
37. Bouzigon E, Nadif R, Thompson EE, et al. A common variant in RAB27A gene is associated with fractional exhaled nitric oxide levels in adults. *Clin Exp Allergy*. 2015;45(4):797-806.
38. Kabesch M, Schedel M, Carr D, et al. IL-4/IL-13 pathway genetics strongly influence serum IgE levels and childhood asthma. *J Allergy Clin Immunol*. 2006;117(2):269-274.
39. Stenberg Hammar K, Hedlin G, Konradsen JR, et al. Subnormal levels of vitamin D are associated with acute wheeze in young children. *Acta paediatrica*. 2014;103(8):856-861.
40. Thomsen SF, Ferreira MA, Kyvik KO, Fenger M, Backer V. A quantitative genetic analysis of intermediate asthma phenotypes. *Allergy*. 2009;64(3):427-430.
41. Ferreira MA, O'Gorman L, Le Souef P, et al. Variance components analyses of multiple asthma traits in a large sample of Australian families ascertained through a twin proband. *Allergy*. 2006;61(2):245-253.
42. Lund MB, Kongerud J, Nystad W, Boe J, Harris JR. Genetic and environmental effects on exhaled nitric oxide and airway responsiveness in a population-based sample of twins. *Eur Respir J*. 2007;29(2):292-298.
43. Wu T, Boezen HM, Postma DS, et al. Genetic and environmental influences on objective intermediate asthma phenotypes in Dutch twins. *Eur Respir J*. 2010;36(2):261-268.
44. Matucci A, Vultaggio A, Maggi E, Kasujee I. Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question? *Respir Res*. 2018;19(1):113.
45. Arbes SJ, Jr., Calatroni A, Mitchell HE, Gergen PJ. Age-dependent interaction between atopy and eosinophils in asthma cases: results from NHANES 2005-2006. *Clin Exp Allergy*. 2013;43(5):544-551.
46. Lambrecht BN, Hammad H. The immunology of asthma. *Nat Immunol*. 2015;16(1):45-56.
47. Cosmi L, Liotta F, Maggi L, Annunziato F. Role of Type 2 Innate Lymphoid Cells in Allergic Diseases. *Curr Allergy Asthma Rep*. 2017;17(10):66.

48. Smith SG, Chen R, Kjarsgaard M, et al. Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. *J Allergy Clin Immunol*. 2016;137(1):75-86.e78.
49. Asher MI, Keil U, Anderson HR, et al. International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods. *The European respiratory journal*. 1995;8(3):483-491.
50. Nilsson SF, Lilja G, Jarnbert-Pettersson H, Alm J. Relevance of low specific IgE levels to egg, milk and peanut in infancy. *Clin Exp Allergy*. 2019;49(3):308-316.
51. Ullemar V, Lundholm C, Almqvist C. Twins' risk of childhood asthma mediated by gestational age and birthweight. *Clin Exp Allergy*. 2015;45(8):1328-1336.
52. Nino CL, Perez GF, Isaza N, Gutierrez MJ, Gomez JL, Nino G. Characterization of Sex-Based Dna Methylation Signatures in the Airways During Early Life. *Sci Rep*. 2018;8(1):5526.
53. Gordon L, Joo JE, Powell JE, et al. Neonatal DNA methylation profile in human twins is specified by a complex interplay between intrauterine environmental and genetic factors, subject to tissue-specific influence. *Genome Res*. 2012;22(8):1395-1406.
54. van Dongen J, Slagboom PE, Draisma HH, Martin NG, Boomsma DI. The continuing value of twin studies in the omics era. *Nat Rev Genet*. 2012;13(9):640-653.

Table 1. Descriptive statistics of the study individuals.

	Current asthma†, n = 127		No current asthma, n = 465		p-value
	mean (SD)	n (%)	mean (SD)	n (%)	

Age (y)	12.3 (1.5)	127 (100)	12.6 (1.4)	465 (100)	0.04
Age at sampling-time (y)	12.3 (1.6)	127 (100)	12.6 (1.4)	465 (100)	0.04
Sex					
Male		73 (57.5)		249 (53.5)	0.43
Female		54 (42.5)		216 (46.5)	
Parental education					
< 9 y completed		0		0 (0)	0.16
9–12 y completed		34 (26.8)		105 (22.6)	
>12 y completed		93 (73.2)		360 (77.4)	
Any parental asthma[¶]					
Yes		58 (45.7)		72 (15.5)	<.001
No		66 (52.0)		374 (80.4)	
Missing		3 (2.4)		19 (4.1)	
Smoking mother, current					0.14
Yes		10 (7.9)		54 (11.6)	
No		70 (55.1)		220 (47.3)	
Missing		47 (37.0)		191 (41.1)	
Smoking father, current					
Yes		13 (2.4)		35 (7.5)	0.36
No		68 (53.5)		252 (54.2)	
Missing		46 (36.2)		178 (38.3)	
FE_{No}:					
≥18.25 ppb.‡		55 (43.3)		92 (19.8)	<.001
Arithmetic mean	25.5 (22.1)	122 (96.1)	15.8 (13.0)	436 (93.8)	<.001
Geometric mean	18.0	122 (96.1)	12.9	436 (93.8)	<.001
Allergen-specific IgE level, kU_A/L					
Arithmetic mean	19.6 (26.3)	115 (90.6)	7.0 (17.9)	433 (93.1)	<.001
Geometric mean	2.3	115 (90.6)	0.3	433 (93.1)	<.001
IgE positive: §					
No		40 (31.5)		283 (60.9)	<.001
Yes		75 (59.1)		150 (32.3)	

Eosinophil cell count, 1*10⁹ counts/L					
Arithmetic mean	0.4 (0.4)	115 (90.6)	0.3 (0.3)	422 (90.8)	<.001
Geometric mean	0.3	115 (90.6)	0.2	421 (90.5)	<.001
ICS regularly[#]					
No		83 (65.4)		464 (99.8)	<.001
Yes		44 (34.6)		1 (0.2)	
Zygosity:					
MZ		72 (56.7)		205 (44.1)	0.01
DZ		55 (43.3)		260 (55.9)	
Season at sampling-time:[‡]					
Spring (March-April-May)		38 (29.9)		105 (22.6)	
Summer (June-July-Aug)		26 (20.5)		60 (12.9)	0.004
Autumn (Sept-Oct-Nov)		53 (41.7)		214 (46.0)	
Winter (Dec-Jan.Feb)		10 (7.9)		86 (18.5)	

SD = Standard Deviation, n=number of participants, † Asthma is derived from questionnaire by parents answering the question: 'Does your child have asthma?' (n=20 had missing value on 'current asthma' but the method allows missing values in the outcome-variables), ‡ Parts per billion (ppb), § Sensitization to aeroallergens: sIgE≥0.35 kU_A/L to Phadiatop (birch, timothy, mugwort, cat, dog, horse, house dust mites, and mold), ¶ Based on whether either the mother or father answered 'yes' if they had asthma on the questionnaire, # Regular use of ICS during the last 12 months, ‡there were no within-twin pair variability regarding season at sampling-time.

Table 2. Twin correlations

MZ twins		DZ twins	All twins
Correlation	Estimate (95% CI)	Estimate (95% CI)	Estimate (95% CI)
r _{ph} Eosinophils and IgE level [†]	0.26 (0.12–0.39)	0.24 (0.12–0.35)	0.24 (0.16–0.33)
r _{ph} Eosinophils	0.29 (0.07–0.51)	-0.05 (-0.27–0.18)	0.11 (-0.06–0.27)

and Asthma [‡]			
r _{ph} Eosinophils and FE _{NO} [†]	0.34 (0.20–0.47)	0.28 (0.17–0.39)	0.30 (0.22–0.39)
r _{ph} IgE level and Asthma [‡]	0.33 (0.13–0.52)	0.29 (0.11–0.47)	0.30 (0.16–0.44)
r _{ph} IgE level and FE _{NO} [†]	0.45 (0.34–0.57)	0.40 (0.30–0.50)	0.42 (0.35–0.50)
r _{ph} Asthma and FE _{NO} [‡]	0.21 (0.00–0.42)	0.17 (-0.02–0.35)	0.18 (0.04–0.33)
ICC Asthma [¶]	0.83 (0.66–1.00)	0.48 (0.14–0.83)	NA
ICC FE _{NO} [†]	0.67 (0.56–0.77)	0.34 (0.20–0.48)	NA
ICC IgE level [†]	0.63 (0.55–0.72)	0.26 (0.11–0.41)	NA
ICC Eosinophils [†]	0.56 (0.43–0.69)	0.30 (0.14–0.46)	NA
CTCT Eosinophils and IgE level [†]	0.18 (0.04–0.32)	0.02 (-0.11–0.14)	NA
CTCT Eosinophils and Asthma [‡]	0.28 (0.06–0.50)	0.00 (-0.22–0.21)	NA
CTCT Eosinophils and FE _{NO} [†]	0.17 (0.02–0.32)	0.12 (0.00–0.24)	NA
CTCT IgE level and Asthma [‡]	0.29 (0.10–0.47)	0.09 (-0.11–0.29)	NA
CTCT IgE level and FE _{NO} [†]	0.32 (0.20–0.45)	0.14 (0.02–0.26)	NA
CTCT Asthma and FE _{NO} [‡]	0.17 (-0.04–0.39)	-0.08 (-0.28–0.12)	NA

bold = statistically significantly different from zero. r_{ph} = phenotypic correlation, i.e. the correlation between variables within individuals, within-twin/cross-trait. ICC = intra-class correlation, i.e. the correlation between the same variable measured in one twin and in her co-twin, cross-twin/within-trait. CTCT = cross-twin/cross-trait correlation, i.e. the correlation between one variable in one twin and another in the co-twin, IgE level=continuous value of allergen-specific IgE level.

Note: Correlations adjusted for covariates sex, age at examination, and ICS-medication (asthma not adjusted for ICS). [†] = Pearson correlation, [‡] = Biserial correlation, [¶] = Tetrachoric correlation

Table 3. Results from multivariate modeling. Phenotypic correlation from best-fitting model; due to Asthma and FE_{NO} and/or from Eosinophils and IgE level.

	AE	AE – relative contributions
total $r_{ph}^{\dagger}$	0.19 (0.05-0.33)	NA
$r_{ph-a}^{\dagger}$	0.14 (-0.02-0.29)	0.73 (0.18-1.27)
$r_{ph-e}^{\dagger}$	0.05 (-0.05-0.16)	0.27 (-0.27-0.82)
r_{ph-a} : IgE level [‡]	0.10 (0.03-0.18)	0.54 (0.03-1.06)
r_{ph-a} : Eosinophils [‡]	0.01 (-0.02-0.04)	0.05 (-0.11-0.21)
r_{ph-a} : Shared between IgE level and eosinophils [‡]	0.02 (-0.01-0.06)	0.13 (-0.05-0.32)
r_{ph-a} : Asthma and $FE_{NO}^{\dagger}$	-0.00 (-0.15-0.15)	-0.00 (-0.78-0.78)
r_{ph-e} : IgE level [‡]	0.01 (-0.02-0.04)	0.07 (-0.11-0.24)
r_{ph-e} : Eosinophils [‡]	-0.01 (-0.04-0.03)	-0.04 (-0.23-0.16)
r_{ph-e} : Shared between IgE level and eosinophils [‡]	0.00 (-0.01-0.02)	0.01 (-0.06-0.09)
r_{ph-e} : Asthma and $FE_{NO}^{\dagger}$	0.04 (-0.05-0.14)	0.23 (-0.26-0.73)

r_{ph} =phenotypic correlation, r_{ph-a} =part of phenotypic correlation which is attributable to additive genetic effect, r_{ph-e} =part of phenotypic correlation which is attributable to unique environmental effect, IgE level=continuous value of allergen-specific IgE level, NA=not applicable. **bold** =statistically significantly different from 0. [†] = Biserial correlation, [‡] = Pearson correlation

Figure 1. Cholesky AE model. Path diagram of association within one individual. Capital A and E refer to latent factors, lower-case a and e refer to path coefficients onto the observed variables. Observed variables are depicted with a square. IgE level=continuous value of allergen-specific IgE level. Note: Variances of latent factors not depicted, but assumed fixed at 1.

Figure 2. Explained phenotypic correlation between asthma and FE_{NO}, re-weighted by sampling probability and adjusted for ICS-use. The height of the bar represents the phenotypic correlation, r_{ph} , which is further decomposed into genetic and environmental parts explained by allergen-specific IgE-levels, Eosinophils, Asthma and FE_{NO}. The color coding represents additive genetic effects, factor A (reddish), or unique environmental effects, factor E (blueish), on the total r_{ph} . IgE level=continuous value of allergen-specific IgE level.




Figure 1.

Figure 1. Cholesky AE model.




Figure 2.

Figure 2. Explained phenotypic correlation between asthma and FE_{NO} .

Online Supplement

Genetic effects of allergen-specific IgE-levels on exhaled nitric oxide in schoolchildren with asthma: the STOPPA twin study

Anna M. Hedman, Ralf Kuja-Halkola, Anne K. Örtqvist, Marianne van Hage, Catarina Almqvist,
Björn Nordlund

Supplemental Methods

Statistical Analyses

Calculated contributions to the correlations between asthma and FE_{NO}

To quantify which sources of variation contributed to the association between asthma and FE_{NO} we used results from the fitted models. In the so-called “Cholesky model” sources of variance and covariance to the left may contribute to variance and covariance to the right, but not *vice versa*. However, the specific ordering from left to right of the variables does not affect the overall model fit (i.e., the likelihood); any ordering will produce a positive semi-definite symmetric matrix interpretable as a covariance matrix. The different ordering will only change the specific parameters’ estimates, and the interpretation of these. Thus, the parameters from any fitted Cholesky model may be used to calculate the parameters that would have been found for the same data with a different ordering of the variables.

The chosen order in the current study (allergen-specific IgE level, eosinophils, asthma, and FE_{NO}) produces a contribution from eosinophils to the association between asthma and FE_{NO} which is uniquely associated with eosinophils, and not influenced by any variance shared between eosinophils and allergen-specific IgE level, since covariance between allergen-specific IgE level and eosinophils is subsumed by the first factor (i.e., furthest to the left). Hence the set-up produces unique contribution from eosinophils.

To find the corresponding contribution from allergen-specific IgE level, independent of eosinophils, we find the parameters that would have been produced if the model had been

fitted with a different variable order – i.e., had allergen-specific IgE level and eosinophils swapped place. Below we explain how this was done.

Let

$$F = \begin{bmatrix} f_{11} & 0 & 0 & 0 \\ f_{12} & f_{22} & 0 & 0 \\ f_{13} & f_{23} & f_{33} & 0 \\ f_{14} & f_{24} & f_{34} & f_{44} \end{bmatrix},$$

and

$$\begin{aligned} Cov \begin{pmatrix} \text{IgE levels} \\ \text{eosinophils} \\ \text{asthma} \\ \text{FE}_{\text{NO}} \end{pmatrix} &= FF^T \\ &= \begin{bmatrix} f_{11}^2 & f_{11}f_{12} & f_{11}f_{13} & f_{11}f_{14} \\ f_{11}f_{12} & f_{12}^2 + f_{22}^2 & f_{12}f_{13} + f_{22}f_{23} & f_{12}f_{14} + f_{22}f_{24} \\ f_{11}f_{13} & f_{12}f_{13} + f_{22}f_{23} & f_{13}^2 + f_{23}^2 + f_{33}^2 & f_{13}f_{14} + f_{23}f_{24} + f_{33}f_{34} \\ f_{11}f_{14} & f_{12}f_{14} + f_{22}f_{24} & f_{13}f_{14} + f_{23}f_{24} + f_{33}f_{34} & f_{14}^2 + f_{24}^2 + f_{34}^2 + f_{44}^2 \end{bmatrix}. \end{aligned}$$

Here “ f_{pq} ” represent the latent variable loading from latent variable associated with new variance to observed variable p to the observed variable q . In the ADCE-models the F is separated into corresponding matrices A, D, C , and D with associated a_{pq}, d_{pq}, c_{pq} , and e_{pq} .

If we focus on the submatrix of dimensions 3x3, and replace the variables with generic X, Y , and Z , let this model be called modA:

$$Cov \begin{pmatrix} X \\ Y \\ Z \end{pmatrix} = FF^T = \begin{bmatrix} f_{11} & 0 & 0 \\ f_{12} & f_{22} & 0 \\ f_{13} & f_{23} & f_{33} \end{bmatrix} \begin{bmatrix} f_{11} & f_{12} & f_{13} \\ 0 & f_{22} & f_{23} \\ 0 & 0 & f_{33} \end{bmatrix} = \begin{bmatrix} f_{11}^2 & f_{11}f_{12} & f_{11}f_{13} \\ f_{11}f_{12} & f_{12}^2 + f_{22}^2 & f_{12}f_{13} + f_{22}f_{23} \\ f_{11}f_{13} & f_{12}f_{13} + f_{22}f_{23} & f_{13}^2 + f_{23}^2 + f_{33}^2 \end{bmatrix}$$

Thus, the contribution from the second variable, Y , to the third, Z , may be interpreted as uniquely related to Y independent of X since covariance with X has already been accounted for. However, the ordering of X and Y is arbitrary with regards to model fit, suppose we have another set up as (modB)

$$\begin{aligned}
Cov \begin{pmatrix} Y \\ X \\ Z \end{pmatrix} &= GG^T = \begin{bmatrix} g_{11} & 0 & 0 \\ g_{12} & g_{22} & 0 \\ g_{13} & g_{23} & g_{33} \end{bmatrix} \begin{bmatrix} g_{11} & g_{12} & g_{13} \\ 0 & g_{22} & g_{23} \\ 0 & 0 & g_{33} \end{bmatrix} \\
&= \begin{bmatrix} g_{11}^2 & g_{11}g_{12} & g_{11}g_{13} \\ g_{11}g_{12} & g_{12}^2 + g_{22}^2 & g_{12}g_{13} + g_{22}g_{23} \\ g_{11}g_{13} & g_{12}g_{13} + g_{22}g_{23} & g_{13}^2 + g_{23}^2 + g_{33}^2 \end{bmatrix}.
\end{aligned}$$

Here, similarly to above, the contribution of X to Z can be seen as unique and independent of that from Y .

As noted above, both versions will produce the same fit to observed covariance matrices. Therefore, when fitting version modA, one may re-calculate to find the estimates that would have been found if it had been version modB instead.

To do this, assume f -parameters known (estimated) and g -parameters unknown. We have six equations and six unknowns:

$$\begin{aligned}
f_{11}^2 &= g_{12}^2 + g_{22}^2, \\
f_{11}f_{12} &= g_{11}g_{12}, \\
f_{12}^2 + f_{22}^2 &= g_{11}^2, \\
f_{11}f_{13} &= g_{12}g_{13} + g_{22}g_{23}, \\
f_{12}f_{13} + f_{22}f_{23} &= g_{11}g_{13}, \\
f_{13}^2 + f_{23}^2 + f_{33}^2 &= g_{13}^2 + g_{23}^2 + g_{33}^2.
\end{aligned}$$

The solution can be found as (assuming $f_{11}, g_{11}, f_{22}, g_{22}, f_{33}, g_{33}$ all are positive, a reasonable assumption since they represent standard deviations).

$$\begin{aligned}
g_{11} &= \sqrt{f_{12}^2 + f_{22}^2}, \\
g_{12} &= \frac{f_{11}f_{12}}{\sqrt{f_{12}^2 + f_{22}^2}},
\end{aligned}$$

$$g_{13} = \frac{f_{12}f_{13} + f_{22}f_{23}}{\sqrt{f_{12}^2 + f_{22}^2}},$$

$$g_{22} = \frac{f_{11}f_{22}}{\sqrt{f_{12}^2 + f_{22}^2}},$$

$$g_{23} = \frac{f_{13}f_{22} - f_{12}f_{23}}{\sqrt{f_{12}^2 + f_{22}^2}},$$

$$g_{33} = f_{33}.$$

Thus, the unique contribution from Y to the variance of Z can be found as

$$f_{23}^2.$$

And, similarly, the unique contribution from X to Z can be found by

$$g_{23}^2 = \frac{(f_{13}f_{22} - f_{12}f_{23})^2}{f_{12}^2 + f_{22}^2}.$$

Consequently, the variance not explained uniquely by either X or Y is variance explained by something shared. This is the total variance from X or Y on Z minus the uniquely explained:

$$f_{13}^2 + f_{23}^2 - f_{23}^2 - \frac{(f_{13}f_{22} - f_{12}f_{23})^2}{f_{12}^2 + f_{22}^2} = f_{13}^2 - \frac{(f_{13}f_{22} - f_{12}f_{23})^2}{f_{12}^2 + f_{22}^2}.$$

Finally, this conclusion can be extended to the four-variate version (fourth variable indicated by W) by seeing that the solution will be equivalent for the fourth variable included regarding the unique contributions from the first and second variable. Thus, the unique contribution from Y (corresponding to eosinophils in our application) to the covariance between Z and W (corresponding to asthma and FE_{No}) can be found as

$$Cov_{uniqueY} = f_{23}f_{24}.$$

The unique contribution of X (corresponding to allergen-specific IgE level) to the covariance between Z and W can be found as

$$Cov_{uniqueX} = g_{23}g_{24} = \frac{f_{13}f_{22} - f_{12}f_{23}}{\sqrt{f_{12}^2 + f_{22}^2}} \cdot \frac{f_{14}f_{22} - f_{12}f_{24}}{\sqrt{f_{12}^2 + f_{22}^2}}.$$

And the shared contribution from X and Y is the contribution from X and Y not attributable uniquely to either X or Y :

$$Cov_{sharedXY} = f_{13}f_{14} + f_{23}f_{24} - Cov_{uniqueY} - Cov_{uniqueX}.$$

The remaining contribution is attributable to Z and W :

$$Cov_{ZW} = f_{33}f_{34}.$$

Supplemental Results

Assumptions testing

Data Supplement Table E1A-B presents the model-fitting tables of assumptions, where the “Symmetric” and “Assumption” models were tested against the saturated model. The “Assumption” model did not have a statistically significant deterioration of fit when compared to the “Symmetric” model ($p = 0.480$). A slight deviation from symmetry between twin 1 and 2 existed, but we deemed the data appropriate for quantitative genetic analyses.

ETable 1A-B. Model fitting for assumptions between the saturated and nested models (a) and model fitting for assumptions between the symmetric and nested models (b).

ETable 1A.

base	comparison	ep	minus2LL	df	AIC	diffLL	diffdf	p
Saturated	<NA>	95	5186.45	2324	538.45	NA	NA	NA
Saturated	Symmetric	57	5245.87	2362	521.87	59.42	38	0.015
Saturated	Assumption	44	5258.46	2375	508.46	72.01	51	0.028

ETable 1B.

base	comparison	ep	minus2LL	df	AIC	diffLL	diffdf	P
Symmetric	<NA>	57	5245.87	2362	521.87	NA	NA	NA
<i>Symmetric</i>	<i>Assumption</i>	<i>44</i>	<i>5258.46</i>	<i>2375</i>	<i>508.46</i>	<i>12.59</i>	<i>13</i>	<i>0.480</i>

ep=estimated parameters, minus2LL=minus 2 times log likelihood, df=degrees of freedom, AIC=Akaike's criterion, diffLL=differences in minus 2 log likelihood, diffdf=differences in degrees of freedom, p=p-value, NA=not applicable. *Italic*=most parsimonious model (i.e., best chosen model according to AIC).

ETable 2A. Quantitative model fitting, saturated model compared with nested models

base	comparison	ep	minus2LL	df	AIC	diffLL	diffdf	p
Saturated	NA	95	5186.45	2324	538.45	NA	NA	NA
Saturated	ACE	44	5261.25	2375	511.25	74.80	51	0.017
Saturated	ADE	44	5263.67	2375	513.67	77.22	51	0.010
Saturated	AE	34	5266.36	2385	496.36	79.90	61	0.053
Saturated	CE	34	5304.90	2385	534.90	118.44	61	<0.001

Ep=estimated parameters, minus2LL=minus 2 times log likelihood, df=degrees of freedom, AIC=Akaike's criterion, diffLL=differences in minus 2 log likelihood, diffdf=differences in degrees of freedom, p=p-value, NA=not applicable.

ETable 2B. Quantitative model fitting, ACE model compared with other models

Base	Comparison	Ep	Minus2LL	Df	AIC	DiffLL	Diffdf	P-value
ACE	NA	44	5261.25	2375	511.25	NA	NA	NA
ACE	ADE	44	5263.67	2375	513.67	2.423	0	NA
<i>ACE</i>	<i>AE</i>	<i>34</i>	<i>5266.36</i>	<i>2385</i>	<i>496.36</i>	<i>5.10</i>	<i>10</i>	<i>0.884</i>
ACE	CE	34	5304.90	2385	534.90	43.64	10	<0.001

Base= model to be compared. Comparison=model compared to "Base" model. Ep=estimated parameters. Minus2LL=minus 2 times log likelihood. Df=degrees of freedom. AIC=Akaike's Information Criterion. DiffLL=differences in minus 2 times log likelihood. Diffdf=differences in degrees of freedom. NA=not applicable. *Italic*=most parsimonious model (i.e., best chosen model according to AIC).

ETable 3. Results from multivariate modeling. Phenotypic correlation divided into A, D, C and E due to Asthma and FE_{NO} and/or from Eosinophils and allergen-specific IgE level.

	ACE	ADE	CE
total r ⁺	0.19 (0.04-0.33)	0.19 (0.04-0.33)	0.20 (0.06-0.34)
r due to A ⁺	0.32 (0.04-0.60)	-0.00 (-0.54-0.53)	NA
r due to D ⁺	NA	0.14 (-0.38-0.67)	NA
r due to C ⁺	-0.17 (-0.40-0.06)	NA	0.07 (-0.07-0.21)
r due to E ⁺	0.03 (-0.08-0.15)	0.05 (-0.06-0.15)	0.13 (0.03-0.23)
r due to A: IgE level ⁺	0.14 (-0.02-0.29)	0.17 (-0.37-0.71)	NA
r due to A: Eosinophils ⁺	-0.01 (-0.08-0.06)	0.10 (-0.24-0.45)	NA
r due to A: Shared between IgE level and Eosinophils ⁺	0.02 (-0.07-0.12)	0.00 (-0.22-0.22)	NA

r due to A: Asthma and FE _{NO} [†]	0.17 (-0.14-0.49)	-0.28 (-0.96-0.41)	NA
r due to D: IgE level [‡]	NA	0.11 (-0.50-0.71)	NA
r due to D: Eosinophils [‡]	NA	0.14 (-0.37-0.66)	NA
r due to D: Shared between IgE level and Eosinophils [‡]	NA	-0.11 (-0.71-0.49)	NA
r due to D: Asthma and FE _{NO} [†]	NA	0.00 (-0.00-0.00)	NA
r due to C: IgE level [‡]	-0.15 (-0.37-0.08)	NA	0.08 (0.01-0.15)
r due to C: Eosinophils [‡]	-0.11 (-0.63-0.42)	NA	0.02 (-0.02-0.06)
r due to C: Shared between IgE level and Eosinophils [‡]	0.09 (-0.42-0.59)	NA	0.02 (-0.01-0.06)
r due to C: Asthma and FE _{NO} [†]	-0.00 (-0.00-0.00)	NA	-0.05 (-0.19-0.08)
r due to E: IgE level [‡]	0.01 (-0.02-0.04)	0.01 (-0.02-0.05)	0.04 (0.00-0.07)
r due to E: Eosinophils [‡]	-0.01 (-0.06-0.03)	-0.01 (-0.04-0.03)	-0.01 (-0.03-0.02)
r due to E: Shared between IgE level and Eosinophils [‡]	0.00 (-0.01-0.01)	0.00 (-0.01-0.02)	0.01 (-0.01-0.02)
r due to E: Asthma and FE _{NO} [†]	0.03 (-0.06-0.13)	0.03 (-0.06-0.12)	0.10 (0.00-0.19)
Relative r due to A [†]	1.74 (-0.02-3.49)	-0.02 (-2.92-2.88)	NA
Relative r due to D [†]	NA	0.78 (-2.16-3.71)	NA
Relative r due to C [†]	-0.91 (-2.46-0.63)	NA	0.35 (-0.21-0.91)
Relative r due to E [†]	0.18 (-0.41-0.76)	0.24 (-0.30-0.79)	0.65 (0.09-1.21)
Relative r due to A: IgE level [‡]	0.73 (-0.17-1.64)	0.92 (-2.01-3.85)	NA
Relative r due to A: Eosinophils [‡]	-0.05 (-0.44-0.33)	0.55 (-1.34-2.45)	NA
Relative r due to A: Shared between IgE level and Eosinophils [‡]	0.12 (-0.38-0.63)	0.00 (-1.20-1.21)	NA
Relative r due to A: Asthma and FE _{NO} [†]	0.93 (-0.80-2.67)	-1.49 (-5.49-2.50)	NA
Relative r due to D: IgE level [‡]	NA	0.59 (-2.73-3.92)	NA
Relative r due to D: Eosinophils [‡]	NA	0.78 (-2.11-3.67)	NA
Relative r due to D: Shared between IgE level and Eosinophils [‡]	NA	-0.60 (-3.88-2.69)	NA
Relative r due to D: asthma and FE _{NO} [†]	NA	0.00 (-0.00-0.00)	NA

Relative r due to C: IgE level [†]	-0.79 (-2.19-0.61)	NA	0.38 (-0.01-0.78)
Relative r due to C: Eosinophils [‡]	-0.59 (-3.47-2.30)	NA	0.11 (-0.10-0.33)
Relative r due to C: Shared between IgE level and Eosinophils [‡]	0.46 (-2.27-3.20)	NA	0.12 (-0.05-0.28)
Relative r due to C: Asthma and FE _{NO} [†]	-0.00 (-0.00-0.00)	NA	-0.27 (-1.05-0.52)
Relative r due to E: IgE level [†]	0.05 (-0.12-0.23)	0.07 (-0.11-0.26)	0.19 (-0.03-0.40)
Relative r due to E: Eosinophils [‡]	-0.07 (-0.32-0.18)	-0.03 (-0.24-0.18)	-0.04 (-0.16-0.08)
Relative r due to E: Shared between IgE level and Eosinophils [‡]	0.00 (-0.07-0.08)	0.02 (-0.06-0.09)	0.03 (-0.04-0.10)
Relative r due to E: Asthma and FE _{NO} [†]	0.19 (-0.33-0.71)	0.19 (-0.30-0.67)	0.48 (-0.01-0.97)

r=correlation, A=additive genetic effect, C=common environmental effect, D=dominant genetic effect, E=unique environmental effect, IgE level= continuous value of allergen-specific IgE level, NA=not applicable. [†] = Biserrial correlation, [‡] = Pearson correlation

ETable 4A. Included path-coefficients in the AE-model (unstandardized), names of path-coefficients correspond to Figure 1 in main text.

Parameter	Estimate (95% CI)	p
a₁₁	0.50 (0.43-0.56)	<0.001
a₁₂	0.13 (0.04-0.22)	0.006
a₁₃	0.09 (-0.15-0.32)	0.469
a₁₄	0.07 (-0.01-0.14)	0.093
a₂₂	2.03 (1.82-2.24)	<0.001
a₂₃	0.34 (0.15-0.53)	<0.001
a₂₄	0.22 (0.14-0.29)	<0.001
a₃₃	0.83 (0.71-0.96)	<0.001
a₃₄	0.00 (-0.10-0.10)	0.996
a₄₄	0.41 (0.37-0.46)	<0.001
e₁₁	0.43 (0.38-0.48)	<0.001
e₁₂	0.11 (0.03-0.18)	0.009
e₁₃	-0.04 (-0.23-0.16)	0.702
e₁₄	0.11 (0.05-0.16)	<0.001
e₂₂	1.59 (1.44-1.75)	<0.001
e₂₃	0.07 (-0.12-0.26)	0.470
e₂₄	0.12 (0.06-0.18)	<0.001
e₃₃	0.42 (0.22-0.62)	<0.001

e₃₄	0.06 (-0.06-0.18)	0.335
e₄₄	0.30 (0.25-0.34)	<0.001

p=p-value, 95% CI= 95% Confidence Interval, **bold**= statistically significantly different from zero, a=path coefficient for the genetic loadings, e=path coefficient for the environmental loadings, IgE level= continuous value of allergen-specific IgE level.

ETable 4B. Univariate results from 4-variate models

ACE model	Estimate (95% CI)
A Eosinophils	0.41 (0.10-0.72)
D Eosinophils	NA
C Eosinophils	0.14 (-0.11-0.39)
E Eosinophils	0.45 (0.32-0.57)
A IgE level	0.60 (0.45-0.74)
D IgE level	NA
C IgE level	0.02 (-0.09-0.14)
E IgE level	0.38 (0.30-0.46)
A Asthma	0.46 (-0.16-1.09)
D Asthma	NA
C Asthma	0.33 (-0.21-0.88)
E Asthma	0.20 (0.00-0.40)
A FE _{NO}	0.49 (0.23-0.75)
D FE _{NO}	NA
C FE _{NO}	0.15 (-0.07-0.37)
E FE _{NO}	0.36 (0.27-0.46)
ADE-model	
A Eosinophils	0.42 (0.03-0.81)
D Eosinophils	0.16 (-0.23-0.56)
C Eosinophils	NA
E Eosinophils	0.42 (0.31-0.53)
A IgE level	0.42 (-0.14-0.98)
D IgE level	0.21 (-0.36-0.77)
C IgE level	NA
E IgE level	0.37 (0.29-0.45)
A Asthma	0.63 (-0.31-1.57)
D Asthma	0.20 (-0.75-1.15)
C Asthma	NA
E Asthma	0.17 (0.01-0.34)
A FE _{NO}	0.54 (0.15-0.94)
D FE _{NO}	0.11 (-0.29-0.50)
C FE _{NO}	NA
E FE _{NO}	0.35 (0.26-0.44)

AE-model	
A Eosinophils	0.57 (0.46-0.68)
D Eosinophils	NA
C Eosinophils	NA
E Eosinophils	0.43 (0.32-0.54)
A IgE level	0.62 (0.54-0.70)
D IgE level	NA
C IgE level	NA
E IgE level	0.38 (0.30-0.46)
A Asthma	0.82 (0.64-0.99)
D Asthma	NA
C Asthma	NA
E Asthma	0.18 (0.01-0.36)
A FE _{NO}	0.65 (0.56-0.74)
D FE _{NO}	NA
C FE _{NO}	NA
E FE _{NO}	0.35 (0.26-0.44)
CE-model	
A Eosinophils	NA
D Eosinophils	NA
C Eosinophils	0.42 (0.32-0.53)
E Eosinophils	0.58 (0.47-0.68)
A IgE level	NA
D IgE level	NA
C IgE level	0.47 (0.39-0.55)
E IgE level	0.53 (0.45-0.61)
A Asthma	NA
D Asthma	NA
C Asthma	0.69 (0.51-0.87)
E Asthma	0.31 (0.13-0.49)
A FE _{NO}	NA
D FE _{NO}	NA
C FE _{NO}	0.51 (0.42-0.59)
E FE _{NO}	0.49 (0.41-0.58)

A=additive genetic effect (i.e., heritability), C=common environmental effect, D=dominant genetic effect, E= unique environmental effect, IgE level=continuous value of allergen-specific IgE level, NA=not applicable, 95% CI= 95% Confidence Interval

ETable 5. Twin correlations with categorical IgE positive

	MZ twins	DZ twins	All twins
Correlation	Estimate (95% CI)	Estimate (95% CI)	Estimate (95% CI)
r_{ph} Eosinophils and IgE positive [†]	0.28 (0.11-0.45)	0.22 (0.06-0.39)	0.24 (0.13-0.35)
r_{ph} Eosinophils and Asthma [†]	0.29 (0.05-0.53)	-0.05 (-0.29-0.20)	0.11 (-0.12-0.34)
r_{ph} Eosinophils and FE _{NO} [‡]	0.34 (0.20-0.48)	0.28 (0.15-0.41)	0.31 (0.21-0.40)
r_{ph} IgE positive and Asthma [¶]	0.32 (0.04-0.60)	0.43 (0.13-0.74)	0.36 (0.13-0.60)
r_{ph} IgE positive and FE _{NO} [†]	0.51 (0.36-0.66)	0.41 (0.27-0.55)	0.45 (0.35-0.55)
r_{ph} Asthma and FE _{NO} [†]	0.22 (0.01-0.43)	0.18 (-0.04-0.39)	0.19 (-0.02-0.41)
ICC Eosinophils [‡]	0.84 (0.67-1.01)	0.49 (0.12-0.87)	NA
CTCT Eosinophils and IgE positive [†]	0.68 (0.58-0.78)	0.33 (0.18-0.49)	NA
CTCT Eosinophils and Asthma [†]	0.58 (0.33-0.82)	0.26 (-0.06-0.57)	NA
CTCT Eosinophils and FE _{NO} [‡]	0.56 (0.43-0.69)	0.30 (0.13-0.46)	NA
ICC IgE positive [¶]	0.17 (-0.03-0.36)	-0.03 (-0.21-0.16)	NA
CTCT IgE positive and Asthma [¶]	0.28 (0.05-0.52)	-0.01 (-0.25-0.22)	NA
CTCT IgE positive and FE _{NO} [†]	0.18 (0.03-0.33)	0.12 (-0.03-0.26)	NA
ICC Asthma [¶]	0.30 (0.03-0.58)	0.10 (-0.28-0.48)	NA
CTCT Asthma and FE _{NO} [†]	0.36 (0.20-0.53)	0.11 (-0.07-0.29)	NA
ICC FE _{NO} [‡]	0.20 (-0.02-0.41)	-0.08 (-0.33-0.18)	NA


r_{ph} =phenotypic correlation, i.e. the correlation between variables within individuals, within-twin/cross-trait. ICC=intra-class correlation i.e. the correlation between the same variable measured in one twin and in her co-twin, cross-twin/within-trait. CTCT=cross-twin/cross-trait correlation, i.e. the correlation between one variable in one twin and another in the co-twin, IgE positive=categorical value (1/0) of allergen-specific IgE, **bold** =statistically significantly different from 0. [†] = Biserial correlation, [‡] = Pearson correlation, [¶] = Tetrachoric correlation

ETable 6. Results from multivariate modeling with categorical IgE positive. Phenotypic correlation divided into A, D, C and E due to Asthma and FE_{NO} and/or from Eosinophils and IgE positive.

	ACE	ADE	AE	CE
total r [†]	0.20 (0.05-0.34)	0.19 (0.05-0.33)	0.20 (0.06-0.34)	0.21 (0.07-0.35)
r due to A [†]	0.33 (0.06-0.60)	-0.02 (-0.68-0.65)	<i>0.15 (-0.00-0.31)</i>	NA
r due to D [†]	NA	0.17 (-0.49-0.83)	NA	NA
r due to C [†]	-0.16 (-0.38-0.06)	NA	NA	0.08 (-0.06-0.23)
r due to E [†]	0.03 (-0.09-0.14)	0.04 (-0.06-0.14)	<i>0.04 (-0.06-0.14)</i>	0.13 (0.02-0.23)
r due to A: IgE positive [¶]	0.29 (-0.18-0.77)	0.18 (-0.42-0.77)	0.15 (0.01-0.29)	NA
r due to A: Eosinophils [‡]	0.01 (-0.12-0.14)	0.11 (-0.16-0.37)	<i>0.01 (-0.03-0.05)</i>	NA
r due to A: Shared between IgE positive and Eosinophils [‡]	0.01 (-0.12-0.15)	-0.02 (-0.27-0.23)	<i>0.02 (-0.02-0.06)</i>	NA
r due to A: Asthma and FE _{NO} [†]	0.02 (-0.49-0.53)	-0.28 (-0.49--0.07)	<i>-0.03 (-0.21-0.15)</i>	NA
r due to D: IgE positive [¶]	NA	0.15 (-0.49-0.80)	NA	NA
r due to D: Eosinophils [‡]	NA	0.15 (-0.32-0.62)	NA	NA
r due to D: Shared between IgE positive and Eosinophils [‡]	NA	-0.13 (-0.60-0.34)	NA	NA
r due to D: Asthma and FE _{NO} [†]	NA	0.00 (-0.00-0.00)	NA	NA
r due to C: IgE positive [¶]	-0.15 (-0.42-0.13)	NA	NA	0.10 (0.00-0.20)
r due to C: Eosinophils [‡]	-0.16 (-0.38-0.06)	NA	NA	0.03 (-0.02-0.08)
r due to C: Shared between IgE positive and Eosinophils [‡]	0.15 (-0.41-0.70)	NA	NA	0.02 (-0.02-0.06)
r due to C: Asthma and FE _{NO} [†]	-0.00 (-0.00-0.00)	NA	NA	-0.06 (-0.20-0.08)
r due to E: IgE positive [¶]	0.01 (-0.04-0.07)	0.01 (-0.04-0.07)	<i>0.01 (-0.06-0.09)</i>	0.06 (-0.01-0.12)
r due to E: Eosinophils [‡]	-0.01 (-0.06-0.04)	-0.01 (-0.04-0.03)	<i>-0.01 (-0.05-0.04)</i>	-0.01 (-0.03-0.01)
r due to E: Shared between IgE positive and Eosinophils [‡]	0.00 (-0.02-0.03)	0.00 (-0.02-0.03)	<i>0.00 (-0.02-0.03)</i>	0.01 (-0.01-0.03)
r due to E: Asthma and FE _{NO} [†]	0.03 (-0.12-0.17)	0.02 (-0.07-0.12)	<i>0.03 (-0.08-0.14)</i>	0.07 (-0.03-0.18)
Relative r due to A [†]	1.66 (0.05-3.28)	-0.09 (-3.52-3.35)	0.78 (0.28-1.28)	NA
Relative r due to D [†]	NA	0.90 (-2.61-4.40)	NA	NA
Relative r due to C [†]	-0.80 (-2.20-0.59)	NA	NA	0.39 (-0.13-0.92)
Relative r due to E [†]	0.14 (-0.42-0.70)	0.19 (-0.32-0.69)	<i>0.22 (-0.28-0.72)</i>	0.61 (0.08-1.13)
Relative r due to A: IgE positive [¶]	1.47 (-1.19-4.14)	0.91 (-2.15-3.97)	<i>0.77 (-0.05-1.58)</i>	NA
Relative r due to A: Eosinophils [‡]	0.03 (-0.63-0.68)	0.55 (-0.85-1.94)	<i>0.07 (-0.14-0.27)</i>	NA
Relative r due to A: Shared between IgE positive and Eosinophils [‡]	0.06 (-0.62-0.73)	-0.11 (-1.42-1.19)	<i>0.11 (-0.09-0.30)</i>	NA
Relative r due to A: Asthma and FE _{NO} [†]	0.11 (-2.46-2.67)	-1.43 (-3.14-0.28)	<i>-0.16 (-1.14-0.81)</i>	NA
Relative r due to D: IgE positive [¶]	NA	0.80 (-2.61-4.20)	NA	NA

Relative r due to D: Eosinophils [‡]	NA	0.77 (-1.76-3.30)	NA	NA
Relative r due to D: Shared between IgE positive and Eosinophils [‡]	NA	-0.67 (-3.18-1.85)	NA	NA
Relative r due to D: asthma and FE _{NO} [‡]	NA	0.00 (-0.00-0.00)	NA	NA
Relative r due to C: IgE positive [¶]	-0.73 (-2.23-0.76)	NA	NA	0.48 (-0.04-0.99)
Relative r due to C: Eosinophils [‡]	-0.81 (-2.01-0.40)	NA	NA	0.13 (-0.12-0.38)
Relative r due to C: Shared between IgE positive and Eosinophils [‡]	0.73 (-2.06-3.53)	NA	NA	0.09 (-0.10-0.27)
Relative r due to C: Asthma and FE _{NO} [‡]	-0.00 (-0.00-0.00)	NA	NA	-0.30 (-1.09-0.49)
Relative r due to E: IgE positive [¶]	0.06 (-0.23-0.34)	0.07 (-0.20-0.34)	<i>0.07 (-0.30-0.44)</i>	0.27 (-0.07-0.61)
Relative r due to E: Eosinophils [‡]	-0.06 (-0.30-0.19)	-0.03 (-0.21-0.15)	<i>-0.04 (-0.25-0.18)</i>	-0.05 (-0.15-0.06)
Relative r due to E: Shared between IgE positive and Eosinophils [‡]	0.01 (-0.12-0.14)	0.02 (-0.09-0.13)	<i>0.02 (-0.10-0.13)</i>	0.04 (-0.05-0.14)
Relative r due to E: Asthma and FE _{NO} [‡]	0.13 (-0.57-0.83)	0.13 (-0.38-0.63)	<i>0.16 (-0.39-0.72)</i>	0.34 (-0.14-0.83)

r=correlation, A=additive genetic effect, C=common environmental effect, D=dominant genetic effect, E=unique environmental effect, IgE positive=sensitization to aeroallergens (yes/no), NA=not applicable, *italic*=most parsimonious model (i.e., best chosen model), **bold**=significant in the AE-model, IgE positive=categorical value (1/0) of allergen-specific IgE. [†] = Biserial correlation, [‡] = Pearson correlation, [¶] = Tetrachoric correlation



- A unique from Eosinophils
- A unique from IgE-positive
- A shared by IgE-positive and Eosinophils
- A from Asthma and FE_{NO}
- E unique from Eosinophils
- E unique from IgE-positive
- E shared by IgE-positive and Eosinophils
- E from Asthma and FE_{NO}

EFigure 1. Explained correlation between asthma and FE_{NO} re-weighted by sampling probability and adjusted for ICS-use. The height of the bar represents the phenotypic correlation, r_{ph} . The color coding represents additive genetic effects, factor A (reddish), or unique environmental effects, factor E (blueish), on the total r_{ph} . IgE positive=categorical value (1/0) of allergen-specific IgE.

ETable 7. Twin correlations, additionally adjusted for season of sampling-time (spring [March-May], summer [June-August], autumn [September-November], winter [December-February]).

	MZ twins	DZ twins	All twins
Correlation	Estimate (95% CI)	Estimate (95% CI)	Estimate (95% CI)
r_{ph} Eosinophils and IgE level [†]	0.24 (0.11-0.38)	0.22 (0.11-0.34)	0.23 (0.14-0.32)
r_{ph} Eosinophils and Asthma [‡]	0.31 (0.08-0.54)	-0.04 (-0.27-0.18)	0.12 (-0.05-0.29)
r_{ph} Eosinophils and FE _{NO} [†]	0.33 (0.20-0.47)	0.26 (0.15-0.38)	0.29 (0.20-0.38)
r_{ph} IgE level and Asthma [‡]	0.37 (0.17-0.56)	0.32 (0.14-0.50)	0.34 (0.20-0.48)
r_{ph} IgE level and FE _{NO} [†]	0.45 (0.33-0.57)	0.39 (0.29-0.49)	0.42 (0.34-0.49)
r_{ph} Asthma and FE _{NO} [‡]	0.22 (0.01-0.43)	0.17 (-0.01-0.36)	0.20 (0.06-0.34)
ICC Asthma [¶]	0.83 (0.65-1.00)	0.47 (0.12-0.82)	NA
ICC FE _{NO} [†]	0.65 (0.54-0.76)	0.32 (0.18-0.47)	NA
ICC IgE level [†]	0.63 (0.55-0.72)	0.26 (0.11-0.41)	NA
ICC Eosinophils [†]	0.55 (0.42-0.68)	0.28 (0.13-0.44)	NA
CTCT Eosinophils and IgE level [†]	0.16 (0.02-0.31)	0.00 (-0.12-0.13)	NA
CTCT Eosinophils and Asthma [‡]	0.31 (0.09-0.53)	0.00 (-0.21-0.21)	NA
CTCT Eosinophils and FE _{NO} [†]	0.16 (0.01-0.30)	0.10 (-0.02-0.22)	NA
CTCT IgE level and Asthma [‡]	0.33 (0.14-0.52)	0.11 (-0.09-0.31)	NA
CTCT IgE level and FE _{NO} [†]	0.32 (0.19-0.44)	0.12 (0.00-0.24)	NA

CTCT Asthma and FE _{NO} [†]	0.19 (-0.02-0.40)	-0.07 (-0.27-0.12)	NA
---	-------------------	--------------------	----

bold = statistically significantly different from zero. r_{ph} = phenotypic correlation, i.e. the correlation between variables within individuals, within-twin/cross-trait. ICC = intra-class correlation, i.e. the correlation between the same variable measured in one twin and in her co-twin, cross-twin/within-trait. CTCT = cross-twin/cross-trait correlation, i.e. the correlation between one variable in one twin and another in the co-twin, IgE level=continuous value of allergen-specific IgE level.

Note: Correlations adjusted for covariates sex, age at examination, ICS-medication (asthma not adjusted for ICS), and season of sample-time. [†] = Pearson correlation, [‡] = Biserial correlation, [¶] = Tetrachoric correlation

ETable 8A-B. Model fitting for assumptions between the saturated and nested models (a) and model fitting for assumptions between the symmetric and nested models (b). Additionally adjusted for season of sampling-time.

ETable 8A.

base	comparison	ep	minus2LL	df	AIC	diffLL	diffdf	p
Saturated	<NA>	107	5153.56	2312	529.56	NA	NA	NA
Saturated	Symmetric	69	5217.30	2350	517.30	63.74	38	0.006
Saturated	Assumption	56	5228.31	2363	502.31	74.76	51	0.017

ETable 8B.

base	comparison	ep	minus2LL	df	AIC	diffLL	diffdf	P
Symmetric	<NA>	69	5217.30	2350	517.30	NA	NA	NA
Symmetric	Assumption	56	5228.31	2363	502.31	11.02	13	0.609

ep=estimated parameters, minus2LL=minus 2 times log likelihood, df=degrees of freedom, AIC=Akaiques criterion, diffLL=differences in minus 2 log likelihood, diffdf=differences in degrees of freedom, p=p-value, NA=not applicable. *Italic*=most parsimonious model (i.e., best chosen model according to AIC).

ETable 9A. Quantitative model fitting, saturated model compared with nested models, additionally adjusted for season of sampling-time.

base	comparison	ep	minus2LL	df	AIC	diffLL	diffdf	p
Saturated	NA	107	5153.56	2312	529.56	NA	NA	NA
Saturated	ACE	56	5231.21	2363	505.21	77.66	51	0.009
Saturated	ADE	56	5232.49	2363	506.49	78.93	51	0.007
Saturated	AE	46	5235.28	2373	489.28	81.72	61	0.040
Saturated	CE	46	5274.92	2373	528.92	121.37	61	<0.001

Ep=estimated parameters, minus2LL=minus 2 times log likelihood, df=degrees of freedom, AIC=Akaiques criterion, diffLL=differences in minus 2 log likelihood, diffdf=differences in degrees of freedom, p=p-value, NA=not applicable.

ETable 9B. Quantitative model fitting, ACE model compared with other models, additionally adjusted for season of sampling-time.

Base	Comparison	Ep	Minus2LL	Df	AIC	DiffLL	Diffdf	P-value
ACE	NA	56	5231.21	2363	505.21	NA	NA	NA
ACE	ADE	56	5232.49	2363	506.49	1.27	0	NA
ACE	AE	46	5235.28	2373	489.28	4.06	10	0.945
ACE	CE	46	5274.92	2373	528.92	43.71	10	<0.001

Base= model to be compared. Comparison=model compared to “Base” model. Ep=estimated parameters. Minus2LL=minus 2 times log likelihood. Df=degrees of freedom. AIC=Akaike's Information Criterion. DiffLL=differences in minus 2 times log likelihood. Diffdf=differences in degrees of freedom. NA=not applicable. *Italic*=most parsimonious model (i.e., best chosen model according to AIC).

ETable 10. Results from multivariate modeling, additionally adjusted for season of sampling-time. Phenotypic correlation divided into A, D, C and E due to Asthma and FE_{NO} and/or from Eosinophils and allergen-specific IgE level.

	ACE	ADE	AE	CE
total r ⁺	0.20 (0.06-0.34)	0.20 (0.06-0.34)	0.20 (0.06-0.34)	0.22 (0.08-0.36)
r due to A ⁺	0.33 (0.05-0.61)	0.00 (-0.52-0.52)	<i>0.15 (-0.00-0.31)</i>	NA
r due to D ⁺	NA	0.16 (-0.35-0.67)	NA	NA
r due to C ⁺	-0.16 (-0.38-0.06)	NA	NA	0.08 (-0.06-0.22)
r due to E ⁺	0.03 (-0.09-0.14)	0.04 (-0.07-0.15)	<i>0.05 (-0.06-0.15)</i>	0.14 (0.03-0.24)
r due to A: IgE level [‡]	0.15 (-0.01-0.30)	0.18 (-0.28-0.65)	0.12 (0.04-0.20)	NA
r due to A: Eosinophils [‡]	-0.01 (-0.10-0.07)	0.11 (-0.14-0.36)	<i>0.01 (-0.02-0.04)</i>	NA
r due to A: Shared between IgE level and Eosinophils [‡]	0.03 (-0.06-0.12)	-0.01 (-0.26-0.23)	<i>0.03 (-0.01-0.06)</i>	NA
r due to A: Asthma and FE _{NO} ⁺	0.17 (-0.15-0.49)	-0.28 (-0.39--0.16)	<i>-0.00 (-0.15-0.15)</i>	NA
r due to D: IgE level [‡]	NA	0.14 (-0.47-0.75)	NA	NA
r due to D: Eosinophils [‡]	NA	0.16 (-0.28-0.60)	NA	NA
r due to D: Shared between IgE level and Eosinophils [‡]	NA	-0.14 (-0.68-0.40)	NA	NA
r due to D: Asthma and FE _{NO} ⁺	NA	0.00 (-0.00-0.00)	NA	NA
r due to C: IgE level [‡]	-0.13 (-0.36-0.09)	NA	NA	0.09 (0.02-0.16)
r due to C: Eosinophils [‡]	-0.13 (-0.53-0.28)	NA	NA	0.02 (-0.02-0.07)
r due to C: Shared between IgE level and Eosinophils [‡]	0.10 (-0.30-0.50)	NA	NA	0.02 (-0.01-0.06)
r due to C: Asthma and FE _{NO} ⁺	-0.00 (-0.00-0.00)	NA	NA	-0.06 (-0.19-0.07)
r due to E: IgE level [‡]	0.01 (-0.02-0.04)	0.01 (-0.02-0.05)	<i>0.01 (-0.02-0.04)</i>	0.04 (0.00-0.08)
r due to E: Eosinophils [‡]	-0.02 (-0.07-0.03)	-0.01 (-0.05-0.03)	<i>-0.01 (-0.05-0.03)</i>	-0.01 (-0.03-0.01)
r due to E: Shared between IgE level and Eosinophils [‡]	-0.00 (-0.02-0.01)	0.00 (-0.01-0.02)	<i>0.00 (-0.01-0.02)</i>	0.01 (-0.01-0.02)
r due to E: Asthma and FE _{NO} ⁺	0.04 (-0.06-0.14)	0.03 (-0.06-0.13)	<i>0.04 (-0.05-0.14)</i>	0.10 (-0.00-0.20)
Relative r due to A ⁺	1.65 (0.10-3.20)	0.00 (-2.58-2.58)	0.77 (0.24-1.29)	NA
Relative r due to D ⁺	NA	0.80 (-1.83-3.43)	NA	NA

Relative r due to C ⁺	-0.79 (-2.09-0.52)	NA	NA	0.38 (-0.14-0.89)
Relative r due to E ⁺	0.14 (-0.42-0.70)	0.20 (-0.32-0.72)	<i>0.23 (-0.29-0.76)</i>	0.62 (0.11-1.14)
Relative r due to A: IgE level [‡]	0.72 (-0.11-1.55)	0.92 (-1.42-3.26)	<i>0.59 (0.08-1.09)</i>	NA
Relative r due to A: Eosinophils [‡]	-0.07 (-0.50-0.37)	0.55 (-0.72-1.82)	<i>0.06 (-0.09-0.21)</i>	NA
Relative r due to A: Shared between IgE level and Eosinophils [‡]	0.14 (-0.32-0.60)	-0.07 (-1.29-1.14)	<i>0.13 (-0.05-0.30)</i>	NA
Relative r due to A: Asthma and FE _{NO} ⁺	0.86 (-0.76-2.47)	-1.39 (-2.74--0.04)	<i>-0.00 (-0.74-0.73)</i>	NA
Relative r due to D: IgE level [‡]	NA	0.70 (-2.44-3.83)	NA	NA
Relative r due to D: Eosinophils [‡]	NA	0.79 (-1.49-3.07)	NA	NA
Relative r due to D: Shared between IgE level and Eosinophils [‡]	NA	-0.69 (-3.46-2.08)	NA	NA
Relative r due to D: asthma and FE _{NO} ⁺	NA	0.00 (-0.00-0.00)	NA	NA
Relative r due to C: IgE level [‡]	-0.66 (-1.90-0.58)	NA	NA	0.42 (0.03-0.81)
Relative r due to C: Eosinophils [‡]	-0.63 (-2.71-1.45)	NA	NA	0.11 (-0.09-0.31)
Relative r due to C: Shared between IgE level and Eosinophils [‡]	0.50 (-1.53-2.54)	NA	NA	0.11 (-0.05-0.26)
Relative r due to C: Asthma and FE _{NO} ⁺	-0.00 (-0.00-0.00)	NA	NA	-0.26 (-0.98-0.46)
Relative r due to E: IgE level [‡]	0.05 (-0.11-0.22)	0.07 (-0.11-0.24)	<i>0.06 (-0.10-0.22)</i>	0.19 (-0.01-0.39)
Relative r due to E: Eosinophils [‡]	-0.09 (-0.34-0.17)	-0.05 (-0.26-0.17)	<i>-0.05 (-0.26-0.15)</i>	-0.05 (-0.17-0.07)
Relative r due to E: Shared between IgE level and Eosinophils [‡]	-0.00 (-0.08-0.07)	0.01 (-0.06-0.08)	<i>0.01 (-0.06-0.08)</i>	0.03 (-0.04-0.09)
Relative r due to E: Asthma and FE _{NO} ⁺	0.18 (-0.32-0.67)	0.17 (-0.29-0.62)	<i>0.22 (-0.25-0.69)</i>	0.46 (-0.00-0.92)

r=correlation, A=additive genetic effect, C=common environmental effect, D=dominant genetic effect, E= unique environmental effect, IgE level= continuous value of allergen-specific IgE level, NA=not applicable. ⁺ = Biserial correlation, [‡] = Pearson correlation

ETable 11A. Included path-coefficients in the AE-model, additionally adjusted for season of sampling-time (unstandardized), names of path-coefficients correspond to Figure 1 in main text.

Parameter	Estimate (95% CI)	p
a₁₁	0.49 (0.42-0.55)	<0.001
a₁₂	0.12 (0.02-0.21)	0.015
a ₁₃	0.12 (-0.13-0.37)	0.350
a ₁₄	0.06 (-0.02-0.13)	0.153
a₂₂	2.03 (1.81-2.24)	<0.001
a₂₃	0.40 (0.21-0.59)	<0.001
a₂₄	0.21 (0.14-0.28)	<0.001
a₃₃	0.80 (0.66-0.95)	<0.001
a ₃₄	0.00 (-0.11-0.11)	0.992
a₄₄	0.41 (0.36-0.45)	<0.001
e₁₁	0.43 (0.38-0.49)	<0.001
e₁₂	0.11 (0.03-0.19)	0.008
e ₁₃	-0.06 (-0.27-0.15)	0.582
e₁₄	0.11 (0.05-0.16)	<0.001
e₂₂	1.59 (1.43-1.74)	<0.001
e ₂₃	0.06 (-0.12-0.25)	0.503
e₂₄	0.12 (0.06-0.18)	<0.001
e₃₃	0.42 (0.22-0.62)	<0.001
e ₃₄	0.06 (-0.07-0.19)	0.347
e₄₄	0.30 (0.26-0.34)	<0.001

p=p-value, 95% CI= 95% Confidence Interval, **bold**= statistically significantly different from zero, a=path coefficient for the genetic loadings, e=path coefficient for the environmental loadings, IgE level= continuous value of allergen-specific IgE level.

ETable 11B. Univariate results from 4-variate models, additionally adjusted for season of sampling-time.

ACE model	Estimate (95% CI)
A Eosinophils	0.41 (0.10-0.72)
D Eosinophils	NA
C Eosinophils	0.13 (-0.12-0.37)
E Eosinophils	0.46 (0.34-0.59)
A IgE level	0.59 (0.44-0.75)

D IgE level	NA
C IgE level	0.02 (-0.10-0.15)
E IgE level	0.38 (0.30-0.47)
A Asthma	0.51 (-0.11-1.12)
D Asthma	NA
C Asthma	0.29 (-0.25-0.82)
E Asthma	0.21 (0.00-0.41)
A FE _{NO}	0.50 (0.24-0.76)
D FE _{NO}	NA
C FE _{NO}	0.13 (-0.09-0.34)
E FE _{NO}	0.38 (0.27-0.48)
ADE-model	
A Eosinophils	0.39 (0.00-0.79)
D Eosinophils	0.17 (-0.22-0.57)
C Eosinophils	NA
E Eosinophils	0.43 (0.32-0.55)
A IgE level	0.41 (-0.13-0.96)
D IgE level	0.21 (-0.34-0.76)
C IgE level	NA
E IgE level	0.37 (0.29-0.45)
A Asthma	0.60 (-0.34-1.54)
D Asthma	0.23 (-0.72-1.18)
C Asthma	NA
E Asthma	0.17 (0.00-0.34)
A FE _{NO}	0.52 (0.12-0.93)
D FE _{NO}	0.12 (-0.29-0.52)
C FE _{NO}	NA
E FE _{NO}	0.36 (0.27-0.45)
AE-model	
A Eosinophils	0.56 (0.44-0.67)
D Eosinophils	NA
C Eosinophils	NA
E Eosinophils	0.44 (0.33-0.56)
A IgE level	0.62 (0.54-0.70)
D IgE level	NA
C IgE level	NA
E IgE level	0.38 (0.30-0.46)
A Asthma	0.82 (0.64-0.99)
D Asthma	NA
C Asthma	NA
E Asthma	0.18 (0.01-0.36)

A FE _{NO}	0.64 (0.54-0.73)
D FE _{NO}	NA
C FE _{NO}	NA
E FE _{NO}	0.36 (0.27-0.46)
CE-model	
A Eosinophils	NA
D Eosinophils	NA
C Eosinophils	0.41 (0.30-0.51)
E Eosinophils	0.59 (0.49-0.70)
A IgE level	NA
D IgE level	NA
C IgE level	0.47 (0.39-0.55)
E IgE level	0.53 (0.45-0.61)
A Asthma	NA
D Asthma	NA
C Asthma	0.68 (0.49-0.86)
E Asthma	0.32 (0.14-0.51)
A FE _{NO}	NA
D FE _{NO}	NA
C FE _{NO}	0.49 (0.40-0.58)
E FE _{NO}	0.51 (0.42-0.60)

A=additive genetic effect (i.e., heritability), C=common environmental effect, D=dominant genetic effect, E= unique environmental effect, IgE level=continuous value of allergen-specific IgE level, NA=not applicable, 95% CI= 95% Confidence Interval




Figure 2. Explained correlation between asthma and FE_{NO} re-weighted by sampling probability and adjusted for ICS-use, additionally adjusted for season of sampling-time. The height of the bar represents the phenotypic correlation, r_{ph} . The color coding represents additive genetic effects, A (reddish), or

unique environmental effects, E (blueish), on the total r_{ph} . IgE positive=categorical value (1/0) of allergen-specific IgE.